Zydus Lifesciences Patent Challenge in US Over Myrbetriq and Stock Insights
Business and Industry Overview:
Zydus Lifesciences Limited, formerly called Cadila Healthcare Limited, is a top Indian pharmaceutical company. It is a global healthcare provider with expertise in healthcare. Zydus works across the full pharmaceutical value chain. This includes making medicines, active ingredients, animal healthcare products, and wellness products. The company is known in India for offering complete healthcare solutions. Zydus has a rich history. It was founded in 1952 by Mr. Ramanbhai B. Patel (late), who was a first-generation entrepreneur and a leader in the Indian pharmaceutical industry. The company started in the 1950s. In 1995, the company changed its structure and formed Cadila Healthcare under the Zydus group. It grew from a turnover of ₹250 crores in 1995 to more than ₹19,500 crores in FY-24. Zydus is dedicated to improving life in all ways. The company continues to innovate and focus on solving healthcare problems that are not yet addressed. It also works to make communities around the world healthier and happier.
Latest Stock News:
As of April 17, 2025, Zydus Lifesciences Limited’s stock is trading at ₹825.40 on the BSE and ₹998.90 on the NSE. The stock’s price today has been between ₹816.10 and ₹839.15. Over the past 52 weeks, the highest price was ₹1,324.30, and the lowest was ₹795.00. Zydus Lifesciences has a market value of ₹83,055 crore. This is the total value of the company based on its stock price. The company pays a dividend of 0.36%, which means investors get 0.36% of the stock price as dividends. The stock has a Price-to-Earnings (P/E) ratio of 18.95, which helps to understand if the stock price is too high or too low compared to the company’s earnings. Analysts have different opinions about the stock. Three analysts say “strong buy,” nine say “buy,” ten say “hold,” three say “sell,” and two say “strong sell.” This shows that some analysts believe the stock will do well, while others expect it to decline. For the fiscal year 2024, Zydus Lifesciences made a net profit of ₹3,859.50 crore. This is the amount left after all expenses are paid. However, the stock has gone down in recent months. In the past three months, it has fallen by 16.93%. In the past six months, it has dropped by 19.06%. At 14:47 IST on April 17, 2025, Zydus Lifesciences’ stock fell by 7.65% to ₹816.55. It became the biggest loser in the BSE’s ‘A’ group, which has high-value stocks. So far, 2.23 lakh shares were traded on the BSE, much higher than the usual 74,937 shares traded daily over the last month. This shows that more people are trading the stock, likely because of the price drop.
Potentials:
Zydus Lifesciences has many future plans. The company wants to grow in the US market. It plans to launch a new liver medicine called Saroglitazar in the US by early 2026. This medicine helps in liver problems like Primary Biliary Cholangitis (PBC) and MASH. Zydus is also working on special medicines for rare diseases and complex injectables (injection-based medicines). These are harder to make and are used in serious health problems. To grow faster, Zydus wants to join with other companies, buy small companies, or get rights to sell special medicines. This will help the company grow its US business in generic drugs and injections. Zydus is also working on new medicines. It is focusing on making new chemical medicines for problems like heart diseases, inflammation, and fibrosis. The company is also building a group of complex medicines. These include injectables, skin patches (transdermals), and biosimilars. Biosimilars are cheaper copies of expensive modern medicines. Zydus also wants to work more in the rare disease area. It has already bought a medicine for Menkes disease, a rare illness. Zydus is entering new business areas too. It now wants to make products in medical devices, health tests (diagnostics), and nutrition. For this, it bought Naturell India Pvt. Ltd., the company that makes Ritebite Max Protein bars. This helps Zydus enter the protein and nutrition market. The company is also working with other groups. It has a joint venture with Perfect Day Inc. to make animal-free protein products. It has a partnership with CVS Caremark to sell medicines in the US. Zydus is also working with the Gates Foundation to make a new vaccine. This vaccine will fight shigellosis and typhoid. Another new medicine by Zydus is ANVIMO. It helps organ transplant patients. This medicine is made in India and will be affordable and easy to get. Zydus wants to give better and cheaper healthcare to more people. It plans to make modern, useful, and safe medicines for people in India and the world.
Analyst Insights:
- Market capitalisation: ₹ 83,236 Cr.
- Current Price: ₹ 827
- 52-Week High/Low: ₹ 1,324 / 795
- Stock P/E: 18.4
- Dividend Yield: 22.3 %
- Return on Capital Employed (ROCE): 22.3 %
- Return on Equity: 20.7 %
Zydus Lifesciences Ltd is showing strong growth. Its Q4 FY25 results were very good. Net profit grew by 33.34%. It reached ₹1,026 crore. Last year, it was ₹769 crore. Revenue also increased by 16.96%. It became ₹5,832 crore in Q4 FY25. This means the company is selling more. The profit margin also improved. EBITDA margin is now 26%. It was 23.2% last year. This shows the company is managing costs well. For the full year FY25, net profit was ₹4,675 crore. In FY23, it was ₹3,164 crore. This shows the company is growing every year. Zydus also reduced its debt. In FY23, total debt was ₹1,195 crore. Now, in FY25, it is only ₹190 crore. This is a big improvement. The company is almost debt-free. This helps in saving interest costs. Its Return on Capital Employed (ROCE) is 22.34%. This means Zydus is using its money well. It is earning a good profit from the money it uses. The Price-to-Earnings (P/E) ratio is 18.4. This is low compared to other pharma companies. It means the stock is not too expensive. The company’s Earnings Per Share (EPS) is also growing. Profit margins are improving. The company is working well in India and outside India. It also launched new products in the U.S. market. Zydus has a strong base. It is growing, reducing debt, and increasing profit. It is a stable and healthy company. These are good signs for investors.